Petros Pharmaceuticals is a pharmaceutical company focused on men's health therapeutics with a range of capabilities including sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. Co. is engaged in the commercialization and development of Stendra®, a PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). Co. also markets its own line of ED products in the form of vacuum erection device products. In addition to ED products, Co. has a license to develop and commercialize H100, a topical formulation candidate for the treatment of acute Peyronie's disease. The PTPI stock yearly return is shown above.
The yearly return on the PTPI stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PTPI annual return calculation with any dividends reinvested as applicable (on ex-dates).
|